Skip to main content

Bristol Myers Squibb guidance

  • BMY · NYSE
  • Pharmaceuticals
  • S&P 500
$62.93−0.79%Close 16 Nov 2026 · Market value $124.3B

Bristol Myers Squibb gives no forecast in figures in its latest earnings release (29 Oct 2026). Many companies give their outlook on the call only, or none at all.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Guidance against results above 1 · within 0 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$46.00B to $47.50BGiven once—To come
EPS · AdjustedFY2026$6.05 to $6.35Given once—To come
Gross margin · AdjustedFY202669% to 70%Given once—To come
Operating expenses · AdjustedFY2026$16.30BGiven once—To come
Operating expensesFY2026About $16.50BGiven once—To come
Tax rate · AdjustedFY202618%Given once—To come
RevenueFY2025$45.80B to $46.80BRaised once$48.19BAbove the range

BMY in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.